HBS (Human BioSystems) secures $5 million equity credit line:
This article was originally published in Clinica
Executive Summary
Human BioSystems (HBS), a developer of biological preservation systems for blood platelets and donor organs, is to receive a maximum of $5m in common stock purchases over the next three years from Dutchess Private Equities Fund. According to Harry Masuda, HBS' president and CEO, the funding will allow the completion of its human infusion studies carried out with its blood platelet preservation solution and, eventually, with its donor organ preservation system. The Palo Alto, California company estimates the market for its products to exceed $300m in 2004.